Borer Denton & Associates’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Other funds holding NVO
DAM
F
Borer Denton & Associates's NVO Position: Q1 2026 in Review
Borer Denton & Associates reduced its Novo Nordisk (NVO) stake by 3% in Q1 2026, selling an estimated $106K and leaving 73,287 shares worth $2.69M. The position accounts for 0.96% of the portfolio, ranked #23.
Borer Denton & Associates first reported a position in NVO in Q1 2022 and has held it in 17 quarters since. The position peaked at $16.4M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Borer Denton & Associates held 73,287 shares of Novo Nordisk worth $2.69M as of Q1 2026.
- Borer Denton & Associates sold 2,245 Novo Nordisk shares in Q1 2026, an estimated $106K.
- Novo Nordisk made up 0.96% of Borer Denton & Associates's portfolio in Q1 2026, its #23 holding.
- Borer Denton & Associates first reported a position in Novo Nordisk in Q1 2022 and has held it in 17 quarters since.
- Borer Denton & Associates's Novo Nordisk position peaked at $16.4M in Q2 2024.
- 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Borer Denton & Associates's 13F filing for Q1 2026, filed 12 May 2026.